A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

Trial Profile

A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs DCR PHXC (Primary)
  • Indications Primary hyperoxaluria
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 17 Aug 2017 According to a Dicerna Pharmaceuticals media release, the company expect to commence human clinical trials in the first quarter of 2018. I have added information to this study only. Please update when more clear information become available.
    • 08 May 2017 This trial is expected to begin in the first quarter of 2018, according to a Dicerna Pharmaceuticals media release.
    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top